camrelizumab; famitinib malate for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 May 2021: Trial registered, NCT04906993
  2. 23 Jul 2021: Trial started, NCT04906993

The trials

NCT04906993: Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

State
Under way
Phase
Phase 3
People
443 taking part
Started
23 Jul 2021
Primary completion
10 Jun 2025
Arms
camrelizumab combined with famitinib malate
Results
None posted
  1. 28 May 2021: Trial registered
  2. 23 Jul 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.